Trial Profile
A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine Plus Capecitabine Maintenance Treatment Versus Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 20 May 2015 Planned End Date changed from 1 Aug 2012 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 30 Jun 2012 Interim tolerability results presented at the 14th World Congress on Gastrointestinal Cancer.
- 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.